This hypothesis establishes that Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs) [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in Alzheimer's Disease. [1]
Type: Disease Model [2]
Confidence Level: Established (Century-old consensus) [3]
Diseases Associated: Alzheimer's Disease, Down syndrome (trisomy 21), Cerebral Amyloid Angiopathy [4]
Amyloid precursor protein (APP) undergoes proteolytic processing via two pathways: [5]
The γ-secretase complex includes: [6]
| Species | Length | Aggregation | Toxicity | [7]
|---------|--------|-------------|----------| [8]
| Aβ1-38 | 38 aa | Low | Minimal | [9]
| Aβ1-40 | 40 aa | Moderate | Moderate | [10]
| Aβ1-42 | 42 aa | High | High | [11]
| Aβ1-43 | 43 aa | Very high | Very high | [12]
Aβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].
Dystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:
Tau is a microtubule-associated protein encoded by the MAPT gene:
In AD, tau becomes abnormally phosphorylated at >45 sites:
Key phosphorylation sites:
Kinases involved:
NFTs consist of paired helical filaments (PHFs) and straight filaments:
NFTs follow a predictable anatomical progression (Braak staging) [8]:
| Stage | Regions Affected | Clinical Correlation |
|---|---|---|
| I-II | Transentorhinal | Preclinical |
| III-IV | Limbic (hippocampus, amygdala) | MCI |
| V-VI | Isocortical | Dementia |
The amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:
Supporting evidence:
Challenging evidence:
Current models suggest Aβ initiates a cascade, but multiple factors determine progression:
| Evidence Type | Strength | Key Studies |
|---|---|---|
| Histopathology | Strong | [1, 4, 8] |
| Genetic Studies | Strong | [13, 14, 15] |
| Biomarker Studies | Strong | [16, 17, 18] |
| Animal Models | Strong | [19, 20] |
| Clinical Trials | Moderate | [21, 22] |
| Protein/Gene | Role | Relevance |
|---|---|---|
| APP | Aβ precursor | Genetic cause of familial AD |
| PSEN1 | γ-secretase | Most common familial AD gene |
| PSEN2 | γ-secretase | Less common familial AD |
| APOE | Lipid transport | Major genetic risk factor |
| TREM2 | Microglial receptor | Genetic risk factor (late onset) |
| MAPT | Tau protein | Tau gene, risk for tauopathies |
| BIN1 | Bridging integrator | GWAS hit for sporadic AD |
The NIA-AA research framework uses biomarker evidence:
"AD" is now defined by A+T+ status, regardless of clinical symptoms [17].
| Stage | Biomarkers | Clinical |
|---|---|---|
| Preclinical | A+ T- N- | Normal cognition |
| MCI due to AD | A+ T+ N- | Mild impairment |
| Dementia due to AD | A+ T+ N+ | Dementia |
Approved anti-amyloid therapies:
In development:
Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12(2):65-72. 2011. ↩︎
De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016;164(4):603-615. 2016. ↩︎
Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704-706. 1991. ↩︎
Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(5):1977-1981. 1993. ↩︎
Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-99. 2012. ↩︎
Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. Nat Rev Drug Discov. 2018;17(5):297-312. 2018. ↩︎
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's Dement. 2018;14(4):535-562. 2018. ↩︎
Palmqvist S, van der Giessen L, Stomrud E, et al. Blood biomarkers to detect early-stage Alzheimer's disease. JAMA Neurol. 2024;81(3):231-241. 2024. ↩︎
Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. Nat Rev Drug Discov. 2024;23(3):201-218. 2024. ↩︎
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. Neurobiol Aging. 2003;24(7):997-1007. 2003. ↩︎
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. 2023. ↩︎
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2023;389(1):42-53. 2023. ↩︎